# Gilead Sciences (GILD) — Earnings

GILD · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/gild/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$6.75 |
| EPS estimate | −$7.26 |
| EPS surprise | +7.03% |
| Revenue surprise | +5.47% |
| Revenue | $7.8B |
| Revenue estimate | $7.4B |
| Reported | Aug 4, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/882095/000088209526000031/gild-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/b890b5af-ebc9-aca6-f397-a9a26e33e2b2.html) |

Gilead reported Q2 2026 results on August 4, 2026. It posted a loss of $6.75 per share, smaller than the expected loss of $7.26, a 7.03% positive surprise. Revenue was $7.8 billion, 5.47% above the $7.4 billion consensus. Compared with Q2 2025, revenue rose about 10% from $7.1 billion, while EPS swung from a profit of $2.01 to the loss.

The loss stands apart in the table. Gilead was profitable in 18 of the last 20 quarters, mostly earning between $1.34 and $2.47 per share. The only other loss was Q1 2024, at $1.32 per share. Annual EPS was $7.27 in 2022, $6.72 in 2023 and $4.61 in 2024, then rose about 77% to $8.15 in 2025. The first half of 2026 adds up to a $4.72 loss. Revenue has stayed within $6.3 billion to $7.9 billion a quarter, with the high in Q4 2025. Over the last 20 quarters, Gilead topped the EPS estimate 16 times.

Gilead reported Q3 results between October 27 and November 7 in each of the past five years. That points to late October or early November 2026 for the next report. It will show whether EPS returns to profit after the Q2 loss.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 4, 2026 | −$7.26 | −$6.75 | 7.03% | $7.4B | $7.8B |
| Q1 2026 | May 7, 2026 | $1.91 | $2.03 | 6.31% | $6.9B | $7.0B |
| Q4 2025 | Feb 10, 2026 | $1.81 | $1.86 | 2.76% | $7.7B | $7.9B |
| Q3 2025 | Oct 30, 2025 | $2.13 | $2.47 | 15.85% | $7.4B | $7.8B |
| Q2 2025 | Aug 7, 2025 | $1.96 | $2.01 | 2.55% | $7.0B | $7.1B |
| Q1 2025 | Apr 24, 2025 | $1.78 | $1.81 | 1.66% | $6.8B | $6.7B |
| Q4 2024 | Feb 11, 2025 | $1.74 | $1.90 | 9.35% | $7.2B | $7.6B |
| Q3 2024 | Nov 6, 2024 | $1.53 | $2.02 | 32.03% | $7.0B | $7.5B |
| Q2 2024 | Aug 8, 2024 | $1.61 | $2.01 | 25.05% | $6.7B | $7.0B |
| Q1 2024 | Apr 25, 2024 | −$1.49 | −$1.32 | 11.60% | $6.4B | $6.7B |
| Q4 2023 | Feb 6, 2024 | $1.76 | $1.72 | -2.18% | $7.1B | $7.1B |
| Q3 2023 | Nov 7, 2023 | $1.92 | $2.29 | 19.49% | $6.8B | $7.1B |
| Q2 2023 | Aug 3, 2023 | $1.64 | $1.34 | -18.42% | $6.5B | $6.6B |
| Q1 2023 | Apr 27, 2023 | $1.52 | $1.37 | -10.07% | $6.3B | $6.4B |
| Q4 2022 | Feb 2, 2023 | $1.52 | $1.67 | 10.02% | $6.6B | $7.4B |
| Q3 2022 | Oct 27, 2022 | $1.43 | $1.90 | 33.28% | $6.1B | $7.0B |
| Q2 2022 | Aug 2, 2022 | $1.52 | $1.58 | 4.23% | $5.9B | $6.3B |
| Q1 2022 | Apr 28, 2022 | $1.80 | $2.12 | 17.50% | $6.3B | $6.6B |
| Q4 2021 | Feb 1, 2022 | $1.59 | $0.69 | -56.69% | $6.6B | $7.2B |
| Q3 2021 | Oct 28, 2021 | $1.76 | $2.65 | 50.79% | $6.3B | $7.4B |

## Frequently Asked Questions

### When did Gilead Sciences (GILD) last report earnings?

Gilead Sciences last reported on Aug 4, 2026, covering fiscal Q2 2026.

### Did GILD beat earnings estimates?

Yes. Gilead Sciences reported EPS of −$6.75 for Q2 2026 against a −$7.26 estimate — a 7.03% beat.

### How much revenue did GILD report last quarter?

Gilead Sciences reported $7.8B in revenue for Q2 2026, against a consensus estimate of $7.4B.

## Similar Stocks

- [VRTX](https://www.lighthorse.io/tickers/vrtx) — Vertex Pharmaceuticals Incorporated - Common Stock
- [PFE](https://www.lighthorse.io/tickers/pfe) — Pfizer, Inc. Common Stock
- [ABBV](https://www.lighthorse.io/tickers/abbv) — AbbVie Inc. Common Stock
- [MRNA](https://www.lighthorse.io/tickers/mrna) — Moderna, Inc. - Common Stock
- [MRK](https://www.lighthorse.io/tickers/mrk) — Merck & Company, Inc. Common Stock (new)
- [REGN](https://www.lighthorse.io/tickers/regn) — Regeneron Pharmaceuticals, Inc. - Common Stock
- [AMGN](https://www.lighthorse.io/tickers/amgn) — Amgen Inc. - Common Stock
- [LGND](https://www.lighthorse.io/tickers/lgnd) — Ligand Pharmaceuticals Incorporated - Common Stock
- [VIR](https://www.lighthorse.io/tickers/vir) — Vir Biotechnology, Inc. - Common Stock
- [BMY](https://www.lighthorse.io/tickers/bmy) — Bristol-Myers Squibb Company Common Stock

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).